Introduction: The Real-World Evidence Paradox
Real-world evidence for medical devices is reshaping the regulatory landscape at a time when medical innovation faces a major bottleneck. Traditional clinical evidence based on randomized controlled trials (RCTs) is becoming increasingly difficult to generate due to rising costs, long timelines, and operational complexity.
At the same time, the digital health ecosystem continuously produces massive amounts of data through electronic health records, patient registries, and connected devices. This structural gap between traditional evidence generation and real-world data availability is pushing regulatory authorities to evolve.
The Food and Drug Administration (FDA) now recognizes real-world evidence for medical devices as valid scientific evidence in regulatory decision-making. In France, health authorities are also increasingly integrating real-world evidence into health technology assessment and reimbursement decisions.
Clinical practice is no longer just a care setting—it is becoming a continuous regulatory laboratory.
Real-World Evidence and the Rise of Registries: Clinical Trials at Scale
Registries have become a cornerstone of real-world evidence for medical devices. A registry is defined as a structured system that collects standardized data on a specific population over time.
The FDA identifies registries as key sources of real-world data capable of supporting regulatory submissions. Several examples illustrate this transformation:
- Data from the Swedish Coronary Angiography and Angioplasty Register (SCAAR) have supported label expansions for coronary angiography systems
- In the United States, the Americas Hernia Society Quality Collaborative (AHSQC) registry has been used to support 510(k) submissions for robotic surgery systems
These real-world evidence approaches offer major advantages:
- Reduced development costs
- Faster time to market
- More representative patient populations
In France, this strategy aligns with the use of the “Système National des Données de Santé” (SNDS), which enables large-scale real-world data analyses.
The Digital Revolution: Software and Connected Devices as Clinical Evidence
Digital technologies are profoundly transforming real-world evidence for medical devices. The FDA now recognizes multiple new data sources, including:
- Data generated directly by medical devices
- Patient-reported outcomes
- Algorithm-derived data
These sources are now fully integrated into regulatory-grade real-world evidence.
A notable example is the mobile contraceptive application Natural Cycles. The FDA accepted real-world data from more than 15,000 users collected under routine conditions. These real-world evidence data, analyzed within a robust methodological framework, contributed to demonstrating the device’s effectiveness.
This marks a significant shift: real-world evidence is no longer supplementary—it is becoming central to regulatory approval.
An Ethical Breakthrough: Studying Hard-to-Reach Populations
Real-world evidence for medical devices also addresses key ethical limitations of traditional clinical trials.
It enables:
- The study of specific or vulnerable populations
- The avoidance of burdensome or unethical trials
- The use of already available healthcare data
The FDA confirms that real-world evidence can complement—or in some cases replace—clinical trial data when trials are difficult or impractical to conduct.
Globalization of Evidence: A Strategic Lever
Another major evolution is the increasing acceptance by the FDA of data generated outside the United States.
This approach allows:
- Better valorization of European data
- Faster access to the US market
- Optimization of global development strategies
For European manufacturers, real-world evidence for medical devices becomes a strategic asset in international regulatory pathways.
The FDA Framework: Relevance and Reliability
The FDA’s 2025 guidance structures real-world evidence for medical devices around two key pillars:
Relevance
- Data availability (including reliable device identification via Unique Device Identification – UDI)
- Data linkage across sources with validated methodologies
- Temporal consistency
- Population representativeness
Reliability
- Data collection quality
- Data traceability
- Analytical integrity
The FDA requires that real-world evidence be sufficiently robust to support regulatory decisions. These expectations are closely aligned with European requirements, particularly those of the Haute Autorité de Santé (HAS).
Conclusion: Toward Data-Driven Medicine
Real-world evidence for medical devices is redefining how innovation is evaluated. The FDA’s vision is based on the Total Product Life Cycle (TPLC) approach:
- Data are continuously collected
- Evaluation does not stop at market approval
- Indications can evolve over time
In France and across Europe, this paradigm is reinforced through large-scale data systems like the SNDS and national registries.
For manufacturers, the implications are profound:
- Integrating data strategies early in development
- Structuring real-world data collection
- Ensuring data quality and governance
In this new paradigm, every patient interaction contributes to scientific evidence. Real-world evidence for medical devices is no longer optional—it is becoming a central pillar of regulatory science.
Sources
Examples of Real-World Evidence (RWE) Used in Medical Device Regulatory Decisions.
Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (Dec. 2025)
